专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

JP2007031359A Modified protein production inhibiter 审中-公开
标题翻译：改良蛋白生产抑制剂
公开(公告)号：JP2007031359A
公开(公告)日：2007-02-08
申请号：JP2005217668
申请日：2005-07-27
申请人： Kiyoshi Kurokawa , Toshio Miyata , Tokai Univ , 学校法人東海大学 , 敏男宮田 , 清黒川
发明人： MIYATA TOSHIO , KUROKAWA KIYOSHI
IPC分类号： A61K31/397 , A61K31/545 , A61M1/14 , A61M1/28 , A61P7/08 , A61P13/12 , A61P43/00
摘要： PROBLEM TO BE SOLVED: To provide a modified protein production inhibiter which does not have a hypotensive action and does not cause vitamin B6 deficiency.
SOLUTION: This modified protein production inhibiter uses a compound having a free type or salt type β-lactam structure as an active ingredient. The compound having the free type or salt type β-lactam structure includes penicillin-based compounds (amoxicillin, ampicillin, oxacillin, or the like), cephem-based compounds (cefazolin, cefamandole, cefalexin, or the like), carbapenem-based compounds (thienamycin, imipenem, carpetimycin A or the like), monocyclic β-lactam-based compounds (nocardin, sulfazecin, azthreonam or the like), natural cephem-based compounds and other β-lactam-based compounds (cephalosporin C, deacetylcephalosporin C, cephamycin A, or the like).
COPYRIGHT: (C)2007,JPO&INPIT
摘要翻译：待解决的问题：提供不具有降血压作用并且不引起维生素B6缺乏症的改良的蛋白质产生抑制剂。解决方案：该修饰的蛋白质生产抑制剂使用具有游离型或盐型β-内酰胺结构的化合物作为活性成分。具有游离型或盐型β-内酰胺结构的化合物包括青霉素类化合物（阿莫西林，氨苄青霉素，苯唑西林等），头孢类化合物（头孢唑啉，头孢氨噻肟，头孢氨苄等），碳青霉烯类化合物（thienamycin，亚胺培南，地毯霉素A等），单环β-内酰胺类化合物（诺卡因，磺胺二甲腈，azthreonam等），天然头孢烯类化合物等β-内酰胺类化合物（头孢菌素C，脱乙酰头孢菌素C，头孢霉素A等）。版权所有（C）2007，JPO＆INPIT

2. 发明专利

JP2003342296A Megsin activity inhibitor 审中-公开
标题翻译： MEGSIN活动抑制剂
公开(公告)号：JP2003342296A
公开(公告)日：2003-12-03
申请号：JP2002149400
申请日：2002-05-23
申请人： Kiyoshi Kurokawa , Toshio Miyata , 敏男宮田 , 清黒川
发明人： KUROKAWA KIYOSHI , MIYATA TOSHIO
IPC分类号： A61K38/00 , A61P13/12 , A61P43/00 , C07K7/08
摘要： PROBLEM TO BE SOLVED: To obtain a polypeptide inhibiting the activity of Megsin and to provide an application of the same. SOLUTION: This invention provides the polypeptide inhibiting the activity of Megsin and a composition for therapy and/or prevention of mesangial proliferative glomerulonephritis that contains the polypeptide inhibiting the activity of Megsin as an active component. The polypeptide inhibiting the activity of Megsin is useful for therapy of prevention of mesangial proliferative glomerulonephritis because the Megsin induces the mesangial proliferative glomerulonephritis. COPYRIGHT: (C)2004,JPO
摘要翻译：待解决的问题：为了获得抑制Megsin活性的多肽并提供其应用。解决方案：本发明提供了抑制Megsin活性的多肽和用于治疗和/或预防肾小球增生性肾小球肾炎的组合物，其含有抑制Megsin作为活性成分的活性的多肽。抑制Megsin活性的多肽可用于预防肾小球增生性肾小球肾炎的治疗，因为Megsin诱导肾小球膜增生性肾小球肾炎。版权所有（C）2004，JPO

3. 发明专利

JP2004325444A Protein modifier production inhibitor and evaluation method thereof 审中-公开
标题翻译：蛋白质改性剂生产抑制剂及其评估方法
公开(公告)号：JP2004325444A
公开(公告)日：2004-11-18
申请号：JP2004109556
申请日：2004-04-02
申请人： Kiyoshi Kurokawa , Toshio Miyata , Tokai Univ , 学校法人東海大学 , 敏男宮田 , 清黒川
发明人： MIYATA TOSHIO , KUROKAWA KIYOSHI
IPC分类号： G01N33/50 , A61K45/00 , A61P3/08 , A61P3/10 , A61P13/12 , G01N33/15 , G01N33/66
摘要： PROBLEM TO BE SOLVED: To actually alleviate type 2 diabetes-like symptoms, by administering a compound having AGEs inhibitory action on an SHR/NDmc-cp rat.
SOLUTION: This evaluation method for a protein modifier production inhibitor has a process of administering a substance to be tested to the SHR/NDmc-cp rat, before and/or after type 2 diabetes-like simptoms are developed, a process for measuring the production level of a saccharified final product in the SHR/NDmc-cp rat and a process for evaluating that the substance to be tested has protein modifier production inhibitory action, when the substance to be tested has a saccharified final product producing level inhibitory action. By this method, a compound usable in the treatment and/or prevention of the disease caused by the production of AGEs can be screened.
COPYRIGHT: (C)2005,JPO&NCIPI
摘要翻译：待解决的问题：通过向SHR / NDmc-cp大鼠施用具有AGEs抑制作用的化合物来实际减轻2型糖尿病样症状。解决方案：蛋白质修饰剂生成抑制剂的评价方法在形成2型糖尿病模拟之前和/或之后具有向SHR / NDmc-cp大鼠施用待测物质的方法，测定SHR / NDmc-cp大鼠中糖化最终产物的生产水平，以及待测试物质具有蛋白质调节剂产生抑制作用的评估方法，当待测物质具有糖化最终产物产生水平抑制作用。通过该方法，可以筛选可用于治疗和/或预防由AGE产生引起的疾病的化合物。版权所有（C）2005，JPO＆NCIPI

4. 发明专利

JP2007131535A Agent for suppressing formation of modified protein 审中-公开
标题翻译：用于抑制形成改性蛋白质的试剂
公开(公告)号：JP2007131535A
公开(公告)日：2007-05-31
申请号：JP2003434051
申请日：2003-12-26
申请人： Kiyoshi Kurokawa , Toshio Miyata , Tokai Univ , 学校法人東海大学 , 敏男宮田 , 清黒川
发明人： MIYATA TOSHIO , KUROKAWA KIYOSHI
IPC分类号： A61K31/43 , A61K31/431 , A61K31/5365 , A61K31/545 , A61K31/546 , A61P3/10 , A61P7/08 , A61P9/10 , A61P13/12 , A61P17/16 , A61P19/02 , A61P25/00 , A61P25/16 , A61P25/28 , A61P27/02 , A61P27/12 , A61P29/00 , A61P39/02 , A61P43/00 , C07D499/42 , C07D499/46 , C07D499/68 , C07D499/76 , C07D501/18 , C07D501/22 , C07D501/36 , C07D501/59 , C07D505/00
摘要： PROBLEM TO BE SOLVED: To provide an agent for suppressing the formation of a modified protein, free from hypotensive action and inducing no vitamin B6 deficiency.
SOLUTION: The agent for suppressing the formation of a modified protein uses a compound having a free or salt-formed β-lactam structure as an active component. The compound having a β-lactam structure includes penicillin compounds (amoxicillin, ampicillin, oxacillin, etc.), cephem compounds (cefazolin, cefamandole, cephalexin, etc.), carbapenem compounds (thienamycin, imipenem, carpetimycin A, etc.), monocyclic β-lactam compounds (nocardin, sulfazecin, azthreonam, etc.), natural cephem compounds and other β-lactam compounds (cephalosporin C, deacetylcephalosporin C, cephamycin A, etc.).
COPYRIGHT: (C)2007,JPO&INPIT
摘要翻译：待解决的问题：提供抑制修饰蛋白质形成的药剂，没有降血压作用并且不引起维生素B6缺乏症。解决方案：用于抑制修饰蛋白质形成的试剂使用具有游离或盐形式的β-内酰胺结构的化合物作为活性成分。具有β-内酰胺结构的化合物包括青霉素化合物（阿莫西林，氨苄青霉素，苯唑西林等），头孢烯化合物（头孢唑啉，头孢氨噻肟，头孢氨苄等），碳青霉烯化合物（硫霉素，亚胺培南，地毯霉素A等），单环 β-内酰胺化合物（nocardin，sulfazecin，azthreonam等），天然头孢烯化合物和其他β-内酰胺化合物（头孢菌素C，脱乙酰头孢菌素C，头霉素A等）。版权所有（C）2007，JPO＆INPIT

5. 发明专利

JP2004309186A Amelioration agent of endoplasmic reticulum stress and its evaluation method 审中-公开
公开(公告)号：JP2004309186A
公开(公告)日：2004-11-04
申请号：JP2003099692
申请日：2003-04-02
申请人： Kiyoshi Kurokawa , Toshio Miyata , Tokai Univ , 学校法人東海大学 , 敏男宮田 , 清黒川
发明人： MIYATA TOSHIO , KUROKAWA KIYOSHI
IPC分类号： G01N33/50 , A61K45/00 , A61P1/00 , A61P3/10 , A61P13/12 , A61P25/00 , A61P25/16 , A61P25/28 , A61P29/00 , C12Q1/02 , G01N33/15
摘要： PROBLEM TO BE SOLVED: To provide an evaluation method of an endoplasmic reticulum stress amerioration action, and a screening method based on the evaluation method.
SOLUTION: This evaluation method of the endoplasmic reticulum amerioration stress action includes a process for measuring a generation level of the endoplasmic reticulum stress in an SHR/NDmc-cp rat. A compound usable for treatment and/or prevention relative to a disease caused by production of the endoplasmic reticulum stress can be screened by selecting a test material for suppressing the generation level of the endoplasmic reticulum stress by utilizing the evaluation method.
COPYRIGHT: (C)2005,JPO&NCIPI

6. 发明专利

JP2003310268A Transcriptional regulatory sequence and use thereof 审中-公开
标题翻译：转录调节序列及其用途
公开(公告)号：JP2003310268A
公开(公告)日：2003-11-05
申请号：JP2002121315
申请日：2002-04-23
申请人： Kiyoshi Kurokawa , Toshio Miyata , 敏男宮田 , 清黒川
发明人： KUROKAWA KIYOSHI , MIYATA TOSHIO
IPC分类号： G01N33/50 , A61K45/00 , A61K48/00 , A61P13/12 , A61P43/00 , C12N15/09 , C12Q1/68 , G01N33/15
摘要： PROBLEM TO BE SOLVED: To provide a transcriptional regulatory DNA. SOLUTION: A genom DNA region containing a sequence of about 4.0 kb on the upstream of a MEGSIN gene is separated and the base sequence is determined. A region positively regulating the transcription region is specified in the genom DNA region. An AP-1 bond motif in the region is found to exhibit an activity to positively regulate the transcription activity. The transcription activity is considerably lowered by deleting the sequence or transducing a variation from/into the sequence by a site-specific mutagenesis. The transcriptional regulatory DNA is useful as a transcriptional regulatory sequence specific to mesangium cell. The DNA is useful also as a transcriptional factor for controlling the expression of MEGSIS gene and the screening of medicines. COPYRIGHT: (C)2004,JPO
摘要翻译：要解决的问题：提供转录调控DNA。解决方案：分离含有在MEGSIN基因上游的约4.0kb的序列的基因组DNA区域，并确定碱基序列。在基因组DNA区域中规定了正调节转录区的区域。发现该区域中的AP-1键基序表现出积极调节转录活性的活性。通过位点特异性诱变缺失序列或转化序列中的变异，显着降低转录活性。转录调控DNA可用作对肾小球系膜细胞特异性的转录调控序列。该DNA也可用作控制MEGSIS基因表达和药物筛选的转录因子。版权所有（C）2004，JPO

7. 发明专利

JP2007031348A Modified protein production-inhibiting compounding agent 审中-公开
标题翻译：改性蛋白生产抑制剂
公开(公告)号：JP2007031348A
公开(公告)日：2007-02-08
申请号：JP2005217509
申请日：2005-07-27
申请人： Kiyoshi Kurokawa , Toshio Miyata , Tokai Univ , 学校法人東海大学 , 敏男宮田 , 清黒川
发明人： MIYATA TOSHIO , KUROKAWA KIYOSHI
IPC分类号： A61K45/06 , A61K31/4355 , A61K31/4422 , A61K31/545 , A61P13/12 , A61P39/06 , A61P43/00
摘要： PROBLEM TO BE SOLVED: To provide a medicine which has a reinforced modified protein production-inhibiting action, and does not cause vitamin B6 deficiency as a side effect. SOLUTION: This medicine having a reinforced modified protein production-inhibiting action is characterized by using a modified protein production-inhibiting compounding agent, such as a β-lactam-based compound or a pyrazoline compound, itself having the modified protein production-inhibiting action and not exhibiting vitamin B6 deficiency as a side effect, and a hypotensive agent such as nifedipine. COPYRIGHT: (C)2007,JPO&INPIT
摘要翻译：待解决的问题：提供具有增强的改性蛋白质生产抑制作用的药物，并且不引起维生素B6缺乏作为副作用。解决方案：具有增强的改性蛋白质产生抑制作用的药物的特征在于使用经修饰的蛋白质生产抑制作用的本身具有改性的蛋白质产生抑制性复合剂，例如β-内酰胺类化合物或吡唑啉化合物，抑制作用，不表现出维生素B6缺乏作为副作用，还有降血糖药如硝苯地平。版权所有（C）2007，JPO＆INPIT

8. 发明专利

JP2004300153A Protein modification product formation inhibitor 审中-公开
公开(公告)号：JP2004300153A
公开(公告)日：2004-10-28
申请号：JP2004080957
申请日：2004-03-19
申请人： Kiyoshi Kurokawa , Toshio Miyata , Tokai Univ , 学校法人東海大学 , 敏男宮田 , 清黒川
发明人： MIYATA TOSHIO , KUROKAWA KIYOSHI
IPC分类号： C07D207/38 , A61K31/402 , A61P43/00
摘要： PROBLEM TO BE SOLVED: To provide a protein modification product formation inhibitor capable of effectively inhibiting the formation of a protein modification product.
SOLUTION: This protein modification product formation inhibitor contains 3-methyl-1-phenyl-2-pyrazolin-5-one (edaravone) which is a compound having a structure of the formula or its pharmacologically acceptable salt. The compound effectively inhibits the formation of AGEs (advanced glycation end products) and ALEs (lipoxidation end products) in an organism and in a dialysate. Diabetic complication, or the like, is treated and prevented by inhibiting the formation of the protein modification product which is a causative substance of tissual disorders.
COPYRIGHT: (C)2005,JPO&NCIPI

9. 发明专利

JP2006305345A Drug for relieving carbonyl stress state and peritoneal dialysate 审中-公开
标题翻译：用于缓解碳应力状态和皮质透析液的药物
公开(公告)号：JP2006305345A
公开(公告)日：2006-11-09
申请号：JP2006113192
申请日：2006-04-17
申请人： Kurokawa Kiyoshi , Toshio Miyata , Tokai Univ , 学校法人東海大学 , 敏男宮田 , 黒川清
发明人： MIYATA TOSHIO
IPC分类号： A61M1/14 , A61K31/15 , A61K31/155 , A61K31/198 , A61K31/4415 , A61K33/44 , A61K45/00 , A61M1/28 , A61P7/08 , B01J20/26 , C12N15/09 , C12Q1/68
摘要： PROBLEM TO BE SOLVED: To provide a drug, a dialysate, and a method for relieving peritoneal disorders accompanying a peritoneal dialysis by inhibiting carbonyl compounds from modifying protein in the peritoneum during the peritoneal dialysis. SOLUTION: Carbonyl compounds formed and accumulated in a peritoneal dialysate can be inactivated or eliminated by a carbonyl compound-trapping agent such as aminoguanidine. Carbonyl compounds formed during the sterilization and storage of the peritoneal dialysate can be eliminated by bringing the compounds into contact with the trapping agent in advance. Furthermore, it is made possible to eliminate carbonyl compounds originating in the blood of a patient which have flowed into the peritoneal cavity as the dialysis proceeds, by adding the trapping agent to the peritoneal dialysate or by circulating the fluid through a carbonyl compound-trapping cartridge. COPYRIGHT: (C)2007,JPO&INPIT
摘要翻译：要解决的问题：提供药物，透析液和通过腹膜透析期间通过抑制羰基化合物修饰腹膜中的蛋白质来缓解腹膜透析引起的腹膜疾病的方法。解决方案：在腹膜透析液中形成和积聚的羰基化合物可以被羰基化合物捕获剂如氨基胍灭活或消除。通过使化合物预先与捕获剂接触可以消除在腹膜透析液的灭菌和储存期间形成的羰基化合物。此外，通过将捕获剂添加到腹膜透析液中或通过使流体循环通过羰基化合物捕获盒，可以消除源自透析进入腹腔的患者的血液中的羰基化合物。版权所有（C）2007，JPO＆INPIT

10. 发明专利

JP2011173904A Carbonyl stress-ameliorating agent 审中-公开
标题翻译：碳纤维应变剂
公开(公告)号：JP2011173904A
公开(公告)日：2011-09-08
申请号：JP2011094578
申请日：2011-04-21
申请人： Kurokawa Kiyoshi , Toshio Miyata , Tokai Univ , 学校法人東海大学 , 敏男宮田 , 黒川清
发明人： MIYATA TOSHIO
IPC分类号： A61K38/00 , A61K38/43 , A61K38/51 , A61K47/48 , A61M1/28 , A61M1/36 , A61P7/08 , A61P43/00
CPC分类号： A61M1/287 , A61K38/51 , A61M1/3687 , A61K2300/00
摘要： PROBLEM TO BE SOLVED: To provide a carbonyl stress-ameliorating agent which can quickly eliminate carbonyl compounds accumulated in the peritoneal dialyzing fluid during peritoneal dialysis of a patient suffered from renal failure.
SOLUTION: This agent is a 3-deoxyglucosone eliminator containing an enzyme having glyoxalase I activity and a carbonyl compound-reducing agent as the active ingredients. By ameliorating carbonyl stress conditions of the peritoneal dialyzing fluid, it results in suppression of reduction in peritoneal functions (dehydration function) caused by carbonyl modification of protein in the abdominal cavity, also in suppression of development of peritoneal sclerosis.
COPYRIGHT: (C)2011,JPO&INPIT

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式